TIMP-2 gene polymorphism is associated with intracerebral hemorrhage

Cerebrovascular Diseases

Volumn 28, Issue 6, 2009, Pages 558-563

  Reuter, Bjoern ^a   Bugert, Peter ^b   Stroick, Mark ^a   Bukow, Simone ^a   Griebe, Martin ^a   Hennerici, Michael G ^a   Fatar, Marc ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Genetic; Intracerebral hemorrhage; Matrix metalloproteinases; SNP; Stroke; Tissue inhibitor of metalloproteinases

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ALLELE; ARTICLE; BASE PAIRING; BRAIN HEMORRHAGE; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; START CODON; TIMP 2 GENE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 70350050764     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000247599     Document Type: Article

References (25)

1. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
2. Fatar M, Stroick M, Griebe M, Hennerici M: Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 2005; 20: 141-151.
3. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030.
4. Hawkins BT, Davis TP: The blood-brain barrier/ neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-185.
5. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, Del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633.
6. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, Chamorro A, Planas AM: Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/ reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23: 1430-1440.
7. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
8. Mun-Bryce S, Rosenberg GA: Matrix metalloproteinases in cerebrovascular disease. J Cerebr Blood Flow Metab 1998; 18: 1163-1172.
9. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP, Del Zoppo GJ: Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 1408-1419.
10. Alvarez-Sabin J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribo M, Santamarina E, Quintana M, Monasterio J, Montaner J: Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004; 35: 1316-1322.
11. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
12. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG: TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576: 203-207.
13. Fatar M, Stroick M, Steffens M, Senn E, Reuter B, Bukow S, Griebe M, Alonso A, Lichtner P, Bugert P, Meitinger T, Wienker TF, Hennerici MG: Single-nucleotiDe polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis 2008; 26: 113-119.
14. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Toast. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
15. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
16. Hammani K, Blakis A, Morsette D, Bowcock AM, Schmutte C, Henriet P, DeClerck YA: Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem 1996; 271: 25498-25505. (Pubitemid 26337925)
17. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165-2170.
18. Den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet 2001; 109: 121-124.
19. Krex D, Rohl H, Konig IR, Ziegler A, Schackert HK, Schackert G: Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms. Stroke 2003; 34: 2817-2821. (Pubitemid 37517748)
20. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.
21. Plesea IE, Camenita A, Georgescu CC, Enache SD, Zaharia B, Georgescu CV, Tenovici M: Study of cerebral vascular structures in hypertensive intracerebral hemorrhage. Rom J Morphol Embryol 2005; 46: 249-256.
22. Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, George SJ: Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006; 113: 2435-2444.
23. Vukasovic I, Tesija-Kuna A, Topic E, Supanc V, Demarin V, Petrovcic M: Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med 2006; 44: 428-434.
24. Rosenberg GA, Estrada EY, Dencoff JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29: 2189-2195.
25. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70: 2364-2370.